See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Nintendo
Donald Trump
Natural Disasters
Baseball
Republican Party
Social Media
US Politics
European Union
Democratic Party
Taxes
Senate
Published • loading... • Updated

OKYO Pharma releases positive long-term stability data for urcosimod in neuropathic corneal pain

Summary by ophthalmologytimes.com
Urcosimod (formerly known as OK-101) has been shown to be stable for over 2 and a half years in single-use ampoules used for administration of the drug to patients.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
ophthalmologytimes.comophthalmologytimes.com

OKYO Pharma releases positive long-term stability data for urcosimod in neuropathic corneal pain

Urcosimod (formerly known as OK-101) has been shown to be stable for over 2 and a half years in single-use ampoules used for administration of the drug to patients.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

ophthalmologytimes.com broke the news in on Monday, March 31, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal